EL7.AI
StocksMedium•16 November 2026•
1 min read

Cardiff Oncology Receives FDA Fast Track for Colorectal Cancer Treatment

Key Facts

1The US FDA granted Fast Track designation to onvansertib for the first-line treatment of RAS-mutated metastatic colorectal cancer.

The US FDA granted Fast Track designation to onvansertib for the first-line treatment of RAS-mutated metastatic colorectal cancer. GlobeNewswire reported that Cardiff Oncology received the designation for its lead drug candidate to be used in combination with standard therapies, aiming to address an unmet medical need for patients with specific genetic mutations.

The regulatory milestone is supported by clinical data from the ongoing CRDF-004 trial, which demonstrated improved response rates. Shares of Cardiff Oncology, trading under the ticker CRDF, closed at $0.7261 on November 13, 2026, prior to the announcement of the FDA designation.

Open on chart